Company Profile (AI Text)
Name: Venomyx Therapeutics
Canonical URL: https://wefunder.com/venomyx.therapeutics
Updated at: 2026-06-02T05:00:16Z

Tagline: EpiPen for snakebites: the antivenom of tomorrow!
Elevator pitch: We're developing Vipax, the world's first portable, shelf-stable, broad-spectrum antivenom for snakebites. Conventional antivenom is outdated: it's expensive, labor-intensive, works for a single species of snake, can only be administered in a hospital, must be kept cold, and has a host of negative side effects for the patient. Our first product, Vipax, elegantly solves these problems while being cheaper to produce.

Key claims:
- Total raised on Wefunder: 290122 | citation: https://wefunder.com/venomyx.therapeutics#claim-total-raised
- Total investors: 496 | citation: https://wefunder.com/venomyx.therapeutics#claim-total-investors

Verified facts:
- Total raised on Wefunder: 290122 | observed_at: 2026-06-02T05:00:16Z | expires_at: 2026-06-03T05:00:16Z
- Total investors: 496 | observed_at: 2026-06-02T05:00:16Z | expires_at: 2026-06-03T05:00:16Z

Computed metrics:
- total_amount_raised: 290122
- total_investors: 496
- team_size: 4
- featured_investor_count: 0
- faq_count: 5
- recent_post_count: 0

Quick facts:
- 10x more effective than conventional antivenom. | citation: https://wefunder.com/venomyx.therapeutics#claim-fact-1
- Our antivenom saved 100% of mice from whole snake venom. | citation: https://wefunder.com/venomyx.therapeutics#claim-fact-2
- Our antivenom is made in bacteria instead of horses = cheaper and faster to produce. | citation: https://wefunder.com/venomyx.therapeutics#claim-fact-3
- Since it's made in bacteria, there are fewer risks of negative side effects in humans. | citation: https://wefunder.com/venomyx.therapeutics#claim-fact-4
- Vipax is stable at room temperatures for portability. | citation: https://wefunder.com/venomyx.therapeutics#claim-fact-5
- International patent for antivenom composition and methods. | citation: https://wefunder.com/venomyx.therapeutics#claim-fact-6
- $250K committed to $1.2M round so far. | citation: https://wefunder.com/venomyx.therapeutics#claim-fact-7

FAQ:
- Q: rather interesting concept and can be part of a first aid kit in areas with high snake bite potential.may i ask if you have factored in the potential of delayed hypersensitivity reactions and serum sickness like effects as well as local or acute generalised anaphylactic reacti...
  A: Hello Palliankal, Thank you for your interest in our mission and for your insightful question. Hypersensitivity reactions are indeed an issue encountered in conventional antivenin treatment and one that we are mitigating through our use of recombinant single domain antibodies. Our antibodies lack the Fab portion and have high sequence homology to human antibodies- two properties that are integral in minimizing patient immune reactions during treatment. We have designed our approach so that Vi...
- Q: Where are you currently operating? What is your overhead? What sources of income do you currently have to keep the lights on?
  A: Hi Anthony, we are working out of the Torrey Pines Science Park Incubator and operating lean! We also have academic collaborations that help to keep costs low. Thanks for your interest!
- Q: What is the total expiration time of Vipax, from the time of production until the time of expiration? Also it was stated that the anti-bodies grown were similar of that to human, are they similar to that of mice as well?
  A: Hi James! These are some excellent questions. Our single domain aintibodies have high thermal stability and have not degraded or lost activitiy in 12 months at room temperature in solution. The ultimate expiration time will be decided through the FDA but it is very likely to be longer than current antivenoms! Also, our antibodies have high sequence homology with human antibodies and not so much with mice which helps to keep side effects to a minimum. Thanks!
- Q: Can you explain the clinical trial design? Wouldn't standard of care be needed in order to get approval in the US? Also do you have any other patents? Is composition and methods enough? Also I saw that there was as company called Venomab that might be doing the same thing. Als...
  A: Hi Raymond, thanks for your questions and interest! Our clinical trial design is well-characterized and does not differ substantially from the regulatory pathway taken by previously approved antivenoms. Single-domain antibodies (nanobodies) have undergone clinical trials already for other indications and performed quite well and so are not considered a new class of drug. We are already in touch with the FDA and plan to have our pre-IND meeting later this year. The other company that you menti...
- Q: What published research articles were used to substantiate your current antibody fragment production process in E. coli?
  A: Hi Cameron, I have plenty of articles I can share with you and even some of our data from expressing our nanobodies in E. coli. Please email me at ddempsey@venomyx.com, looking forward to discussing!